Sana Biotechnology joined the Unicorn Club on June 25, 2020 after raising an $821 million Series D funding round led by F-Prime Capital, Arch Venture Partners, Flagship Pioneering, and other investors. Headquartered in Seattle, Washington, United States, Sana Biotechnology develops genetically engineered cell therapies for oncology, diabetes, CNS disorders, and other conditions, using gene therapy and gene editing approaches to reprogram or replace damaged cells and tissues.
Keep reading to learn how Sana Biotechnology became a leader in cell therapy and genomics.
What Is Sana Biotechnology and What Does It Do?
Founded in 2018, Sana Biotechnology focuses on developing genetically engineered cell therapies to treat a range of disorders, including cancer, diabetes, and central nervous system diseases. Its pipeline includes candidates such as SC291 for Non-Hodgkin lymphoma, SC255 for multiple myeloma, SC451 for diabetes, and SC379 for CNS conditions. The company leverages gene therapy and gene editing to reprogram cells in the body or replace damaged cells and tissues, aiming to provide durable, scalable therapeutic solutions.
How Much Funding Has Sana Biotechnology Raised?
1. Seed Round
- Amount Raised: $20 million
- Date: 2018
- Lead Investors: F-Prime Capital, Flagship Pioneering
- Purpose: Launch company, establish R&D and early cell therapy platform
2. Series A Round
- Amount Raised: $50 million
- Date: 2018–2019
- Lead Investors: F-Prime Capital, Arch Venture Partners
- Purpose: Advance pipeline development, expand laboratory and clinical team
3. Series B Round
- Amount Raised: $150 million
- Date: 2019
- Lead Investors: Flagship Pioneering, F-Prime Capital
- Purpose: Scale cell therapy programs, initiate preclinical studies
4. Series C Round
- Amount Raised: $200 million
- Date: 2019
- Lead Investors: F-Prime Capital, Arch Venture Partners
- Purpose: Expand clinical trials, develop manufacturing capabilities, and hire key talent
5. Series D Round
- Amount Raised: $821 million
- Date: June 25, 2020
- Lead Investors: F-Prime Capital, Arch Venture Partners, Flagship Pioneering, and 8 others
- Purpose: Scale genetic engineering platform, accelerate clinical programs, and expand pipeline
Total Funding Raised: $821 million Latest Funding Date: June 25, 2020 Latest Known Valuation: Unicorn (>$1 billion)
Key Investors
- F-Prime Capital
- Details: Venture capital firm investing in life sciences and biotechnology
- Focus Areas: Genomics, cell therapy, and healthcare innovation
- Arch Venture Partners
- Details: Early-stage VC supporting biotech and technology startups
- Focus Areas: Gene therapy, cell therapy, and breakthrough healthcare technologies
- Flagship Pioneering
- Details: Venture firm building and funding transformative biotechnology companies
- Focus Areas: Gene editing, synthetic biology, and cell-based therapeutics
- HTIF
- Details: Global investment firm backing high-growth healthcare and life sciences companies
- Focus Areas: Biotechnology, immunotherapy, and genomics
- Baillie Gifford
- Details: Long-term investment firm investing in growth-stage companies
- Focus Areas: Biotech, healthcare innovation, and transformative therapeutics
Where Is Sana Biotechnology’s Headquarters?
Sana Biotechnology is headquartered in Seattle, Washington, United States, supporting R&D, clinical, and manufacturing teams for cell therapy and gene editing programs.
What’s Next for Sana Biotechnology?
Sana Biotechnology plans to advance its genetically engineered cell therapy programs into clinical trials, scale manufacturing, and expand its therapeutic pipeline. The company is focused on developing treatments for oncology, diabetes, CNS disorders, and other genetic diseases while leveraging gene editing and cell engineering to create scalable, durable therapies.
Get Investor and Funding Insights with TexAu
TexAu provides verified investor and funding data for companies like Sana Biotechnology. Explore insights on cell therapy, genomics, and high-growth biotech startups transforming healthcare.
Sign up for Free to access real time investor and funding intelligence.